---
title: "Jolly announced a profit forecast, expecting a net profit attributable to the parent company of 368 million to 388 million yuan in the first half of the year, a year-on-year increase of 24.30% to 31.06%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247777572.md"
description: "Jolly expects its net profit attributable to shareholders in the first half of 2025 to be between 368 million yuan and 388 million yuan, a year-on-year increase of 24.30% to 31.06%. The net profit after deducting non-recurring gains and losses is expected to be between 366 million yuan and 386 million yuan, a year-on-year increase of 25.36% to 32.21%. The company's operating revenue is expected to grow by approximately 12% year-on-year, mainly benefiting from the market expansion of core products such as Wuling capsules, Bailing tablets, and Lingze tablets"
datetime: "2025-07-09T08:46:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247777572.md)
  - [en](https://longbridge.com/en/news/247777572.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247777572.md)
---

# Jolly announced a profit forecast, expecting a net profit attributable to the parent company of 368 million to 388 million yuan in the first half of the year, a year-on-year increase of 24.30% to 31.06%

According to the Zhitong Finance APP, Jolly (300181.SZ) disclosed its performance forecast for the first half of 2025, expecting a net profit attributable to shareholders of the listed company to be between 368 million yuan and 388 million yuan, a year-on-year increase of 24.30% to 31.06%. The net profit after deducting non-recurring gains and losses is expected to be between 366 million yuan and 386 million yuan, a year-on-year increase of 25.36% to 32.21%.

During the reporting period, the company continued to strengthen market expansion based on the advantages of its three core products: Wuling Capsules, Bailing Tablets, and Lingze Tablets, which are included in the national essential drug list. The company's operating revenue increased by approximately 12% compared to the same period last year, with Wuling Capsules and Lingze Tablets maintaining good market growth; the sales revenue of the Bailing series accelerated compared to the same period last year. The sales of traditional Chinese medicine formula granules continued to grow year-on-year as the number of registered varieties increased

### Related Stocks

- [300181.CN](https://longbridge.com/en/quote/300181.CN.md)

## Related News & Research

- [Success of Uzbekistan's first London IPO will inspire others, fund chief says](https://longbridge.com/en/news/287033751.md)
- [ACEN Australia's NSW solar output surges 87% as new capacity powers up](https://longbridge.com/en/news/287096598.md)
- [Tata Power's (NSE:TATAPOWER) Problems Go Beyond Weak Profit](https://longbridge.com/en/news/286980045.md)
- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [Uzbekistan raises $604m in landmark dual IPO debut](https://longbridge.com/en/news/286956985.md)